MD Anderson Cancer Center

Phase [asc]	Trial	Trial Status	Site Status	Drug	NCT#
1/2	Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors	Terminated	Closed	CB-839 + Talazoparib	NCT03875313
1/2	[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay)	Active, not recruiting	Closed	neoBOMB1	NCT03872778
1/2	Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion	Recruiting	Active	MRTX1719	NCT05245500